Close
Updates on Tofersen Trials for SOD1-MND

Updates on Tofersen Trials for SOD1-MND

Reading Time: 7 minutes Global biotechnology company Biogen has announced plans to make tofersen, a potential treatment for people whose MND is believed to be driven by mutations in the SOD1 gene, available to more people on an early access programme. Biogen have also revealed that they are conducting a new Phase 3 clinical trial of tofersen in those…

Highlighting the MND researchers of the future – part 1

Highlighting the MND researchers of the future – part 1

Reading Time: 4 minutes This week sees the start of the 30th International Symposium on ALS/MND in Perth, Australia. The Symposium brings together the brightest minds from the MND research and healthcare communities. With 110 oral presentations, and over 420 posters, the Symposium is an opportunity for around 1,000 researchers and healthcare professionals to share new understanding of the…

Transforming skin cells into nerve cells to understand MND gene mutations

Reading Time: 2 minutes In previous research Prof Kevin Talbot and colleagues at the University of Oxford began to understand more about how the C9orf72 gene defect causes human motor neurones to die. These studies were carried out using an impressive piece of lab technology, called induced pluripotent stem cell (iPSC) technology. iPSC technology allows skin cells to be…